Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Long-term Debt

Borrowings due after more than one year.

Ardelyx, Inc.NASDAQ: ARDX

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt rises 34.5% from a year ago

Long-term debt stood at $203.52M at the end of Q1 FY2026, up 34.5% from a year earlier and down 1.4% from the prior quarter.

Context

  • Long-term debt amounted to 40.3% of total assets at the end of Q1 FY2026, up 3.5 pp from a year earlier.
  • Long-term debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +34.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$203.52M-1.4% QoQ
Last fiscal yearDec 2025
$206.48M+36.9% YoY
Year agoMar 2025
$151.3M+34.5% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.5%——
1 year+36.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
206.48M USD
Year-over-year change
+36.9%

Long-term Debt vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's Mar 2026 long-term debt of $203.52M is the highest of the 5 companies compared; the peer median is $15.58M.
  • Its year-over-year change of +34.5% is the highest of 3, against a peer median of -92.9%.
  • Long-term debt amounts to 40.3% of total assets for ARDX, versus a peer median of 4.1%.
ARDX Competitors Peer median
Long-term Debt for ARDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARDXArdelyx, Inc.Mar 2026$203.52M +34.5%—40.3%
MAZEMaze Therapeutics, Inc.Mar 2026$38.83M ——9.3%
XERSXeris Biopharma Holdings, Inc.Mar 2026$31.06M -85.7%-44.8%7.9%
DMACDiaMedica Therapeutics Inc.Mar 2026$97K ——0.2%
AKBAAkebia Therapeutics, Inc.Mar 2026$0 -100.0%+72.9%0.0%
Peer median (excluding ARDX) $15.58M-92.9%+14.1%4.1%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents72.43M96.14M21.47M64.93M68M
Short-term Investments44.26M27.77M162.83M185.17M196.69M
Net Receivables502K7.73M22.03M57.71M71.85M
Inventory03.28M12.45M21.17M17.74M
Other Current Assets15.11M8.41M11.1M13.57M
Total Current Assets133.65M153.6M246.11M356.45M382.32M
Property, Plant & Equipment (Net)15.11M10.52M6.6M3.88M6.98M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.15M25.95M44.87M75.43M112.31M
Total Non-current Assets16.26M36.46M51.47M79.3M119.29M
Total Assets149.91M190.07M297.58M435.75M501.6M
Account Payables4.28M10.86M11.14M16M19.24M
Short-term Debt32.26M26.71M001.48M
Tax Payables00000
Deferred Revenue04.21M7.18M10.69M1.21M
Other Current Liabilities1.24M10.09M15.04M21.48M66.69M
Total Current Liabilities52.82M65.6M50.39M77.83M88.61M
Long-term Debt0049.82M150.85M206.48M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)09.03M8.64M7.23M39.58M
Other Non-current Liabilities4.73M11.25M20.18M25.53M(3.64M)
Total Non-current Liabilities14.48M26.13M80.37M184.64M246.05M
Total Liabilities67.3M91.74M130.76M262.47M334.66M
Common Stock13K20K23K24K24K
Retained Earnings(712.93M)(780.14M)(846.2M)(885.34M)(946.94M)
Accumulated OCI(6K)(54K)224K57K198K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity82.62M98.33M166.82M173.29M166.95M
Total Debt45.5M36.46M55.98M153.44M211.6M
Net Debt(26.92M)(59.68M)34.51M88.51M143.6M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.